Bernhardt G. Zeiher - 04 Jun 2026 Form 4 Insider Report for Amylyx Pharmaceuticals, Inc. (AMLX)

Reporting relationship: Director
Issuer ticker: AMLX
Reported as of: 04 Jun 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 08 Jun 2026, 16:00:20 UTC
Prior SEC filing: 21 May 2026
Next SEC filing: 12 Jun 2026
Source filing: View source filing
Reporting owner signature: /s/ Joshua B. Cohen, as Attorney in Fact

Key filing fact

Bernhardt G. Zeiher filed Form 4 for Amylyx Pharmaceuticals, Inc. (AMLX) on 08 Jun 2026.

Key facts

This page summarizes Bernhardt G. Zeiher's Form 4 filing for Amylyx Pharmaceuticals, Inc. (AMLX).
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 08 Jun 2026, 16:00.

Change

Previous filing in this sequence was filed on 21 May 2026.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001971421 Primary reporting owner

Zeiher Bernhardt G

Relationship: Director
Address: C/O AMYLYX PHARMACEUTICALS, INC., 55 CAMBRIDGE PARKWAY, SUITE 6W, CAMBRIDGE
Signature: /s/ Joshua B. Cohen, as Attorney in Fact
Signature date: 08 Jun 2026

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

AMLX transaction Derivative

Stock Option (right to buy)

Award

Transaction value
Shares: +24,372
Change %
Price: $0.000000^*
Shares after: 24,372
Date: 04 Jun 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 24,372
Exercise price: $14.31
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

The shares subject to this option shall vest in full upon the earlier of (i) June 4, 2027 or (ii) the date of the next annual meeting, subject to the Reporting Person's continuous service to the Issuer through such vesting date.